By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1111 Main Street
Suite 660
Vancouver  Washington  98660  U.S.A.
Phone: 360-980-8524 Fax: 360-980-8549



Company News
CytoDyn (CYDY) Files Protocol For Extended Access To PRO 140 For Patients Who Reach The End Of PRO 140 Pivotal Phase III Trial 10/24/2016 7:52:00 AM
bioMONTR Labs To Provide Testing Services For CytoDyn (CYDY) PRO 140 Clinical Trials 10/14/2016 11:52:46 AM
CytoDyn (CYDY) Announces Favorable Protocol Modifications For Pivotal Phase III Combination Trial With PRO 140 After Positive FDA Meeting 10/6/2016 7:07:08 AM
CytoDyn (CYDY) Announces $10.0 Million Registered Direct Offering 9/12/2016 7:55:21 AM
CytoDyn (CYDY) To Present At Rodman & Renshaw Global Investment Conference On September 12 9/8/2016 7:55:36 AM
CytoDyn (CYDY) Release: Patients Approach Two Years Of Complete HIV Viral Load Suppression In Phase IIb PRO 140 Monotherapy Extension Study 8/23/2016 7:56:21 AM
CytoDyn (CYDY) Announces Investment Community Conference Call For August 19, 2016 8/18/2016 7:41:56 AM
First Patient Enrolled Under Newly Modified Protocol In CytoDyn (CYDY)’s Phase III PRO 140 Combination Study In HIV 7/26/2016 7:44:13 AM
CytoDyn (CYDY) Submits Orphan Drug Application To FDA For Pretreatment With PRO 140 Of Treatment-Naïve HIV Patients 7/21/2016 12:53:29 PM
CytoDyn (CYDY) Submits Protocol for Phase IIb Trial for Treatment Naïve HIV Patients 7/19/2016 8:07:28 AM